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Abstract
Background: The impressive progress in the field of stem cell research in the past decades has provided the
ground for the development of cell-based therapy. Mesenchymal stromal cells obtained from adipose tissue (AD-
MSCs) represent a viable source for the development of cell-based therapies. However, the heterogeneity and
variable differentiation ability of AD-MSCs depend on the cellular composition and represent a strong limitation for
their use in therapeutic applications. In order to fully understand the cellular composition of MSC preparations, it
would be essential to analyze AD-MSCs at single-cell level.
Method: Recent advances in single-cell technologies have opened the way for high-dimensional, high-throughput,
and high-resolution measurements of biological systems. We made use of the cytometry by time-of-flight (CyTOF)
technology to explore the cellular composition of 17 human AD-MSCs, interrogating 31 markers at single-cell level.
Subcellular composition of the AD-MSCs was investigated in their naïve state as well as during osteogenic
commitment, via unsupervised dimensionality reduction as well as supervised representation learning approaches.
Result: This study showed a high heterogeneity and variability in the subcellular composition of AD-MSCs upon
isolation and prolonged culture. Algorithm-guided identification of emerging subpopulations during osteogenic
differentiation of AD-MSCs allowed the identification of an ALP+/CD73+ subpopulation of cells with enhanced
osteogenic differentiation potential. We could demonstrate in vitro that the sorted ALP+/CD73+ subpopulation
exhibited enhanced osteogenic potential and is moreover fundamental for osteogenic lineage commitment. We
finally showed that this subpopulation was present in freshly isolated human adipose-derived stromal vascular
fractions (SVFs) and that could ultimately be used for cell therapies.
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Conclusion: The data obtained reveal, at single-cell level, the heterogeneity of AD-MSCs from several donors and
highlight how cellular composition impacts the osteogenic differentiation capacity. The marker combination (ALP/
CD73) can not only be used to assess the differentiation potential of undifferentiated AD-MSC preparations, but
also could be employed to prospectively enrich AD-MSCs from the stromal vascular fraction of human adipose
tissue for therapeutic applications.
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Introduction
Surgical interventions for bone repair are required for
numerous reasons, such as trauma-resulting non-union
fractures, or diseases including osteoporosis and osteo-
necrosis. Currently, autologous bone grafting is the most
commonly used approach, but has a number of short-
comings such as the limited amount of harvested spon-
giosa and donor site pain [1]. Alternative approaches,
including the use of synthetic bone substitutes, are not
optimal because they lack the osteoinductive properties
which are extremely important for healing large bone
defects [2]. Cell therapies based on ex vivo expanded
mesenchymal stromal stem cells (MSCs) in combination
with appropriate scaffolds may be valuable alternatives
to autologous bone grafting [3]. MSCs hold the ability to
differentiate into osteoblasts and are available from a
wide variety of tissue sources [4]. In particular, human
fat tissue has been demonstrated to be a valuable source
of MSCs—the so-called adipose-derived stromal cells
(AD-MSCs) [3]. An additional advantage of using fat tis-
sue is the relatively simple isolation procedure compared
to autologous bone isolation [5]. We and others have
shown that the combination of AD-MSCs in association
with synthetic calcium phosphate bone substitutes may
be a good alternative to autologous bone grafting [6–10].
Nevertheless, there are drawbacks linked to the use of
MSCs for clinical therapy in humans. In contrast to
other stem cell types (e.g., embryonic stem cells), the
mechanisms that regulate self-renewal and lineage speci-
fication in MSCs are largely unexplored. In particular,
MSC heterogeneity exists among donors, tissue sources,
and within cell populations [11–14]. The knowledge re-
garding how different functional and differentiation
attributes of MSCs are specified at the population level
is insufficient. This poses significant obstacles in efforts
to develop clinical manufacturing protocols that reprodu-
cibly generate functionally equivalent MSC populations
[15, 16]. Currently, MSCs are defined by cell surface phe-
notypes, as well as their functional ability to differentiate
into multiple cell lineages including osteoclast, chondro-
cyte, adipocyte, or skeletal myocyte lineages [17–19]. With
respect to the clinical application of MSCs, much effort
has been directed toward the identification of unique cell
surface markers that could be used to purify cells from
tissues to homogeneity.
In 2006, the International Society for Cell Therapy
(ISCT) published the minimal criteria for defining MSCs
[20]. These criteria comprise, besides plastic adherence
and trilineage differentiation potential (osteogenic, chon-
drogenic, and adipogenic), the expression of CD105, CD73,
and CD90, coincident with the lack of the hematopoietic
markers CD45, CD34, CD14, CD19b, CD79a, and HLA-DR
[20]. Additional markers have been identified over the years
and are widely accepted for characterizing MSCs [21–31].
Even though all these markers were identified through
functional experiments, in the sense that they correlate with
the trilineage potential of the cells, it is not clear how their
distribution and expression correlate with the observed dif-
ferentiation capacity. Furthermore, questions remain open
regarding whether MSCs express any unique surface epi-
topes, and more importantly, it is unknown whether the
epitopes described to date have value in predicting MSC
function.
In recent years, it was attempted to identify subpopu-
lations of MSCs that show enhanced bone regenerative
capability. Of note, most of these studies used a limited
number of markers alone or in combinations, thus making
comparison and reproducibility of the data difficult. It
would be therefore essential to be able to analyze the ex-
pression of the identified markers in toto and at single-cell
level in order to fully understand which subpopulations
are undergoing osteogenic lineage commitment.
Recent advances in single-cell technologies have allowed
multidimensional, high-throughput, and high-resolution
measurements of biological systems. In this study, we ap-
plied cytometry by time-of-flight (CyTOF) to explore the
cellular composition of 17 human AD-MSCs, interrogating
31 markers at single-cell level. The goal of this study was to
investigate the subcellular composition of AD-MSCs in
their naïve state as well as during osteogenic commitment
via unsupervised dimensionality reduction [32], as well as
by supervised representation learning approaches [33]. The
data obtained reveal for the first time, in an unbiased way
and at single-cell level, the heterogeneity of AD-MSCs from
several donors and highlight the presence of subpopulations
of cells with osteogenic lineage commitment properties.
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This information is of paramount importance considering
the emerging need of MSCs for biomedical applications.
Results
Classification of osteogenic differentiation ability of 17
human AD-MSCs
We have isolated 17 AD-MSCs from the stromal vascular
fraction (SVF) of human fat tissue following standard pro-
tocols [34]. We further assessed the trilineage potential of
the established cell lines by inducing differentiation toward
osteogenic, chondrogenic, and adipogenic fate. Expression
of lineage-specific markers during the differentiation
process was monitored by RTQ-PCR (data not shown) and
by classical staining assays (Alizarin Red, Alcian Blue, and
Oil Red: Figs. 1 and S1A) at days 14, 17, and 21. Staining in-
tensity was quantified using a highly standardized, auto-
mated digital image quantification approach [35]. This
approach takes into consideration not only the amount of
deposited dye in the whole cell culture dish but also the
time needed for differentiation [35]. Shortly, for each cell
line, the calculated pixels for each differentiation day (days
14, 17, and 21) were summed up to obtain one single value
per line (Figs. 1a, b and S1A). Next, the lines were catego-
rized into “good,” “intermediate,” and “bad” differentiating
cells based on the interquartile range distribution. We cate-
gorized lines in the 1st quartile as “bad,” lines in the 2nd
and 3rd quartile as “intermediate,” and lines in the 4th
quartile as “good” (Figs. 1a, b and S1A). Cells from different
donors clearly showed variable differentiation abilities
(Figs. 1b, c and S1A). For example, in “good” osteogenic dif-
ferentiating lines, calcium deposition was already detected
at day 14 whereas “bad” lines did not show differentiation
at day 21 but needed in average at least 30 days to fully dif-
ferentiate (Fig. 1c). The “intermediate” AD-MSC lines
showed Alizarin Red staining around day 17 and classified
therefore between the “good” and the “bad” lines (Fig. 1c).
A similar trend was also observed for chondrogenic and
adipogenic differentiation (Figure S1A). Of interest, “good”
lines for one lineage were not necessarily “good” for the
other two lineages and the same was true for “bad” lines
(Figure S1B). These data suggest either an impairment of
the cells to differentiate or the existence of different sub-
populations with varying differentiation potential.
Single-cell, multidimensional analyses reveal high cellular
heterogeneity in AD-MSCs
In order to dissect the differences between the AD-
MSCs obtained from different donors, we firstly per-
formed single-cell analyses with mass cytometry at their
naïve/undifferentiated state. CyTOF allows the simultan-
eous analysis at single-cell level of up to 50 different
parameters using antibodies conjugated with metal iso-
topes [36, 37]. This technique combines flow cytometry
and mass spectrometry and has already been used to
unravel cellular heterogeneity in the context of cancer,
immune diseases, or cellular differentiation [38–40] as
well as for identifying subcellular markers for diseases
[41]. However, this technology was never employed to
characterize human AD-MSCs. We coupled the high di-
mensionality of mass cytometry with advanced cellular
barcoding to simultaneously investigate 31 markers in
17 primary human AD-MSC lines to dissect at single-
cell level their cellular composition (Fig. 2a).
Visualization of the distribution of the 31 markers in
the AD-MSC lines with the dimensionality reduction
method Uniform Manifold Approximation and Projec-
tion (UMAP) [32] highlighted the intra- and inter-donor
heterogeneity (Figs. 2b, c and S2A). Interestingly, all 17
AD-MSC lines formed one compact cloud showing high
degree of similarity among cells not only within the cell
lines but also among donors (Figs. 2b, c and S2A). Des-
pite the high degree of similarity among cells, the ex-
pression profiles of the investigated markers were not
homogeneously distributed over the cloud but showed a
gradient-like distribution all over the 17 AD-MSC lines.
Interestingly, this was also the case for the widely ac-
cepted MSC markers CD73, CD105, and CD90 [20]. The
expression of these key markers mostly co-localized in
the same region of the cloud and was overlapping with
the expression of other markers described in the litera-
ture to be critical for MSCs, such as EGFRα and PDGF
Rα (Figs. 2b and S2A). In agreement with the minimal
criteria definition [20], the negative markers were indeed
not expressed in the AD-MSC lines (Figs. 2b and S2A).
Other markers such as CD146, NG2, CD271, and
STRO-1 were expressed only by a relatively low number
of cells and were heterogeneously distributed over the
cloud (Figure S2A). We next generated UMAPs for each
individual AD-MSC donor for all 31 markers. Although
very small, each marker showed inter-donor variation re-
garding not only the amount of positive cells but also
the expression intensity of the markers (Fig. 2c). These
data clearly highlight in an unprecedented, multiparametric,
and multidimensional way the heterogeneous composition
of AD-MSC from several donors at single-cell level, sug-
gesting the presence of specific subpopulations.
Algorithm-guided identification of an emerging
subpopulation during AD-MSCs’ osteogenic
differentiation
We further wondered whether the variable differenti-
ation ability of the “good” and “bad” AD-MSCs is due to
the presence of specific subpopulations. Since it was pre-
viously shown that lineage specification occurs during
the first 4 days of differentiation [42], we cultured all 17
AD-MSC lines under osteogenic condition and investi-
gated at the single-cell level with CyTOF the population
dynamics. Shortly, at five different time points, cells for
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each of the 17 AD-MSC lines were collected (day 0: un-
differentiated cells, day 1–4: differentiation) and stra-
tegically barcoded (Table S2). At day 4, all samples were
simultaneously stained and processed for CyTOF acqui-
sition (Fig. 3a and Table S1).
Cell density plots on the UMAPs of the 17 AD-MSC
lines during the initial 4 days of differentiation highlighted
an emerging subpopulation, which was very small at day 0
and increased over the differentiation period (Fig. 3b).






























































































Fig. 1 Classification of in vitro osteogenic differentiation potential of 17 AD-MSC lines. a Strategy used for the quantification of differentiation and
AD-MSC classification: (1) Cells were differentiated in vitro into osteogenic lineage, and at three time points (days 14, 17, and 21), they were
stained with Alizarin Red staining. (2) For each cell line, images of the whole well were acquired and pixels were counted and summed for the
three time points (days 14, 17, and 21). (3) Interquartile distribution was applied, and it was decided that the 4th quartile was representing
“good,” the 3rd and the 2nd quartile represented the “intermediate,” and the 1st quartile represented the “bad” differentiating lines. b Sum of the
pixels acquired at the three time points (days 14, 17, and 21) for osteogenic differentiation of all 17 AD-MSC lines and interquartile categorization
into “good,” “intermediate,” and “bad” AD-MSCs. c In vitro differentiation of one representing “good,” one “intermediate,” and one “bad” AD-MSC
after 14, 17, and 21 days under osteogenic condition assessed by Alizarin Red staining. Depicted are triplicates of undifferentiated cells (control)
and cells cultured under differentiation conditions
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the “good” lines whereas in the “bad” lines it was barely
present even at day 4 (Fig. 3b). To further investigate
whether it was possible to discriminate the differentiation
potential of AD-MSC lines at their undifferentiated state,
we applied the CellCNN algorithm [33] to the mass cy-
tometry data obtained at day 0 (undifferentiated state).
Presented with the task of comparing “good” versus “bad”
cell lines, CellCNN detected a subpopulation character-
ized by high alkaline phosphatase (ALP+) expression and
low expression of the MSC marker CD73 (CD73low)
(Fig. 3c). This subpopulation was highly frequent in “good,
” moderately present in the “intermediate,” and almost
absent in the “bad” cell lines and was confirmed and vali-
dated on all later days of the differentiation process
(Fig. 3d). Analysis of the percentages of cells positive for
ALP and CD73 in each category always confirmed signifi-
cant high frequency of ALP+ cells in the “good” lines,
moderate frequency in the “intermediate” lines, and very
low frequency of ALP+ cells in the “bad” lines over the
four osteogenic days (Figure S3A). The percentage of
CD73-positive cells was constant during the 4 differenti-
ation days in the three categories, but significantly in-
creased in the bad lines at day 2 and day 4 compared to



















Fig. 2 Mass cytometry analyses of human AD-MSCs reveal high heterogeneity. a Scheme of mass cytometry analysis on 17 human AD-MSCs
from AD-MSC collection to the identification of osteogenic subpopulations. b UMAPs of selected markers in all 17 analyzed AD-MSC lines. c
UMAPs of three selected markers (CD73, CD105, PDGFR) in 4 AD-MSC donors. Each dot represents one cell. Blue denotes minimal, green
intermediate, and red high expression




































Fig. 3 Identification of AD-MSC osteogenic subpopulation. a Sample collection and CyTOF approach scheme during 4 days of osteogenic
differentiation (d0 = undifferentiated state, d1–d4 = differentiation). b Cell density plots on the UMAPs of the five analyzed days (d0, d1, d2, d3,
d4) during osteogenic differentiation. Once the pool of all 17 AD-MSC lines is represented, once only the “good,” the “intermediate” (interm.), and
the “bad” AD-MSC lines. Highlighted is the emerging population during osteogenic differentiation. Bright color indicates lower density, and dark
color indicates higher cellular density. c Empirical distribution densities of all analyzed 31 marker abundances for the entire cell population (blue)
and the cell subset selected by CellCNN (red). The identified subpopulation is characterized by alkaline phosphatase-positive (ALP+) and CD73low
expressing cells. d Boxplots indicating the frequencies of the ALP+/CD73low subpopulation selected by CellCNN in all “good,” “intermediate”
(interm.), and “bad” osteogenic differentiating lines during the five analyzed days. Error bars represent the mean of the percentage of positive
cells present in “good” (n = 6), “intermediate” (n = 4), and “bad” (n = 7) AD-MSCs
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We further investigated the correlation between ALP+
frequency (measured by CyTOF during the 5 days) and
the ability to differentiate into osteocytes (based on the
quantification of the staining at days 14, 17, and 21). As
expected ALP+ always correlated with the osteogenic
differentiation ability (Figure S3B) confirming once more
that ALP+ expression correlates with osteogenic lineage
commitment. In conclusion, our approach allowed the
identification of an osteogenic subpopulation character-
ized by the markers ALP+/CD73low that hallmarked ex-
clusively the “good” differentiating lines.
ALP+/CD73+ cells possess enhanced osteogenic
differentiation ability
In order to further characterize the identified subpopula-
tion, we selected four AD-MSC lines (F28, F14, F04, and
F22) and sorted three distinct cell subpopulations by
FACS: ALP+/CD73+, ALP−/CD73low, and ALP
−/CD73high. Although CellCNN analysis on CyTOF
data revealed the presence of an ALP+/CD73low popula-
tion, this phenotype was not clearly definable by FACS
sorting. We could select ALP−/CD73high and ALP
−/CD73low, but it was not possible to unambiguously
distinguish between ALP+/CD73low and ALP+/
CD73high cells. For this reason, we selected the double
positive ALP+ and CD73+ (ALP+/CD73+) population
for further experiments (Figure S4A). As a control, we
used for each AD-MSC line unstained cells processed
through the FACS. After sorting, the different subpopu-
lations were directly plated for differentiation into the
three lineages followed by lineage-specific staining at
days 14, 17, and 21 and quantification according to
Eggerschwiler et al. [35]. The sorted ALP+/CD73+ frac-
tion showed enhanced osteogenic differentiation when
compared to the other sorted populations (Figs. 4a, b
and S4B).
ALP+CD73+ marker combination is predictive for
osteogenic potential in undifferentiated AD-MSC
populations
We next assessed whether the marker ALP+ (which is also
CD73+, see Figure S4A) could be used as a predictor for
osteogenic differentiation potential of AD-MSCs in their
undifferentiated state. For this purpose, we selected five
new AD-MSC lines, which had never been characterized
or used in previous experiments. Undifferentiated cells
from the new lines, together with 9 already characterized
lines (as reference cells), were subjected to CyTOF (Table
S3). Quantification of the presence of ALP+ cells in the
new lines allowed a predicted categorization based on the
9 AD-MSCs, into “good,” “intermediate,” and “bad” lines
(Fig. 4c). We further compared the outcome from the
CyTOF data with the differentiation ability observed
in vitro (Fig. 4d). Alizarin Red quantification and the
interquartile categorization of these lines confirmed two
predicted “good” lines, one predicted “intermediate” line,
and two predicted “bad” lines (Figs. 4c, d and S4C-D).
Thus, we could confirm that the presence of the marker
combination ALP+/CD73+ is sufficient to predict the
osteogenic differentiation ability of a donor AD-MSC line
in its undifferentiated state.
ALP+CD73+ marker combination can be used for
monitoring the osteogenic potential of undifferentiated
AD-MSC populations after expansion in vitro
A major problem during in vitro expansion of MSCs
(and also AD-MSCs) is that they show signs of aging
and changes in the subcellular composition, which fi-
nally lead to a decrease of the differentiation potential
over the passages [14]. To follow the dynamic of the cell
composition over prolonged cell culture, we analyzed
with our CyTOF antibody panel 3 “good” and 1 “inter-
mediate” AD-MSC lines (F28, F14, F22, and F05) from
passage 3 (p3) to passage 20 (p20) (Table S4). We could
confirm that the median intensity of expression of CD73
was increasing whereas ALP was rapidly diminishing
after prolonged culture, mirroring the situation observed
in all “bad” lines at p10 (Figs. 4e and S4E).
We next differentiated the cells at p5, p9, and p20, and
we observed a decrease in the differentiation capacity
over the passages and these changes correlate with the
expression of ALP and CD73 (Figs. 4e, f and S4F). In
conclusion, we confirmed that ALP+/CD73+ expressing
cells possess higher osteogenic differentiation potential
and the marker combination of ALP and CD73 can be
used to predict the osteogenic differentiation potential
of cultured AD-MSCs.
ALP+/CD73+ cells are present in the SVF of human fat
tissue
To ultimately prove the clinical utility of the identified ALP
and CD73 marker combination, we investigated whether
ALP+/CD73+ cells were also present in freshly isolated hu-
man adipose stromal vascular fractions (SVFs), and if, upon
isolation, they displayed similar properties as the ALP+/
CD73+ cells present in AD-MSC lines. For this purpose, hu-
man adipose tissues were collected from 3 healthy donors,
and the presence of ALP+/CD73+ cells was investigated.
Immunohistochemical staining revealed the presence of
ALP+/CD73+ located in fat tissue capillaries (Figs. 5a and
S5A). SVFs from the same donors were further processed by
FACS sorting, and the fractions (control: unstained cells
sorted through FACS; CD45−/ALP+/CD73+, CD45−/ALP
−/CD73low, CD45−/ALP−/CD73high) were plated for
osteogenic differentiation (Figs. 5b and S5B). Quantification
of osteogenic differentiation at d14, d17, and d21 confirmed
higher osteogenic differentiation in the ALP+/CD73+ sorted
cells compared to the other ones (Figs. 5b and S5C).



























































































Fig. 4 ALP+/CD73+ markers possess higher and predictive osteogenic potential. a Alizarin Red staining and quantification of F28 AD-MSC line
sorted subpopulations (ALP+/CD73+, ALP−/CD73low, ALP−/CD73high) after 14, 17, and 21 days of osteogenic differentiation. Controls sorted are
unstained cells, which were run through the FACS machine. Depicted is one triplicate of undifferentiated cells (control) and triplicates of cells
cultured under osteogenic differentiation conditions (differentiation). b Quantification of Alizarin Red staining for F04, F14, and F22 AD-MSC lines
for the same sorted subpopulations after 14, 17, and 21 days of osteogenic differentiation. Error bars indicate the triplicates of the staining and
are presented as mean ± s.d. c Predicted categorization based on alkaline phosphatase (ALP) frequency in five new AD-MSC lines (green) and
nine already characterized AD-MSC lines (reference) measured by CyTOF. d Alizarin Red staining at day 21 of the five new AD-MSC lines. Depicted
are triplicates of undifferentiated cells (control) and cells cultured under osteogenic differentiation conditions (differentiation). e Histogram for the
median intensity of expression of CD73 and ALP of F22 “good” AD-MSC line from passage 3 (p3) till passage 20 (p20). Black is the lowest
intensity, and white represents the highest intensity. f Alizarin Red staining and quantification of F22 at passage p5, p9, and p20 after 14, 17, and
21 days of osteogenic differentiation. Error bars indicate the triplicates of the staining and are presented as mean ± s.d. For statistical analyses, the
one-way ANOVA Dunnett’s multiple comparisons test was used to compare the ALP+/CD73+ population with the other sorted fractions within
the same day: *p≤ 0.05, **p≤ 0.01, ***p ≤ 0.001, and ****p≤ 0.0001. ns, not significant
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These data demonstrate that ALP+/CD73+ cells are
present in freshly isolated human fat tissue and possess
enhanced osteogenic potential, representing therefore in-
teresting cells for therapeutic applications.
Discussion
Even with the most effective protocols, different MSC prep-
arations show strong variation in their differentiation per-
formance. One possible explanation for this phenomenon
A
B
control sorted ALP+CD73+ ALP-CD73low ALP-CD73high
Fig. 5 ALP+/CD73+ cells are present in human fat tissue and possess enhanced osteogenic potential. a Immunofluorescence of ALP and CD73 in
human fat tissue. Scale 100 μm. BF, bright field. b Alizarin Red staining and quantification of 3 healthy donors’ SVF after 21 days of osteogenic
differentiation. Depicted is one triplicate of undifferentiated cells (control) and triplicates of cells cultured under osteogenic differentiation
conditions. Error bars indicate the triplicates of the staining and are presented as mean ± s.d. For statistical analyses, the one-way ANOVA
Dunnett’s multiple comparisons test was used to compare the ALP+/CD73+ population with the other sorted fractions within the same day: *p≤
0.05, **p≤ 0.01, and ***p ≤ 0.001. ns, not significant
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is the high heterogenic cellular composition of MSCs, con-
sisting of different cells harboring diverse lineage commit-
ment ability [43]. The high donor-to-donor variability
observed when MSCs are derived from the same tissue of
origin may be due to different factors including donor
health [11, 44], age, MSC availability, and/or self-renewal
capacity [45–47]. However, variability can also be observed
when BM-MSCs were autologously isolated over different
periods of time or even when isolated bilaterally from the
same donor [15], indicating that the cellular composition of
MSCs plays an important role and is highly heterogeneous.
A possibility to explain this heterogeneity is the variable
composition of the tissues used for the establishment of
MSC lines (e.g., amount of blood vessels). Dissecting this
heterogeneity at single-cell level and identifying subpopula-
tions of cells with specific differentiation attributes are ur-
gently needed for developing clinical manufacturing
protocols that reproducibly generate functionally equivalent
MSC populations.
In this study, we have aimed at identifying specific
AD-MSC subpopulations of cells with higher osteogenic
differentiation potential. The novel approach used herein
enabled the simultaneous visualization of 31 selected
markers in 17 primary AD-MSC lines, thereby offering
unprecedented observational dimensionality in a large
sample set. This approach allowed circumvention of the
classical bulk assays most frequently used for character-
izing MSCs and their differentiation potential, which
pool signals across entire cell populations, masking cell-
to-cell variation. Unexpectedly, the dimensionality re-
duction algorithm UMAP revealed a high degree of cel-
lular similarity, as observed from the compact clouds
that all AD-MSC lines generated. This is in contrast to
hematopoietic cells, for example, where UMAPs clearly
separate the different cell subpopulations (Bendall et al.
[37]). Nevertheless, despite the high degree of similarity
among cells, the distribution of the markers within the
clouds was highly heterogeneous, forming in some cases
gradients (such as CD73, EGFR, PDGFR, SOX9) or small
islands (ALP, CD166, STRO-1) (Figs. 2b and S2A). Fur-
thermore, each marker showed inter-donor variation re-
garding not only the amount of positive cells but also
the expression intensity of the markers (Fig. 2c).
Although ALP and CD73 have never been associated
together with osteogenic potential, singularly they were
previously correlated with osteogenic differentiation.
CD73 was shown to regulate bone formation and re-
modeling in intramembranous bone repair [48]. In our
study, we demonstrated that CD73 expression levels in-
versely correlate with the osteogenic differentiation abil-
ity of 17 human AD-MSC primary preparations
(Figs. 4e, f and S4E-F). Tissue nonspecific ALP has been
found in several tissues and cell types, such as activated
B cells or pluripotent embryonic stem cells [49, 50], and
it is an accepted osteoblast marker. CD73 and ALP are
GPI (glycophosphatidylinositol)-anchored ectoenzymes
with 5′-nucleotidase activity; thus, they share similar
functions. CD73 and ALP regulate the extracellular
breakdown of ATP to adenosine [51]. Released ATP
serves as an autocrine or paracrine regulator of both
osteoblast and osteoclast functions [52, 53], and hydroly-
zation of pyrophosphate provides inorganic phosphate to
promote mineralization. The extracellular nucleotide
ATP can be one of the key mediators in bone metabol-
ism, not only as a phosphate source, but also as a signal-
ing molecule via P2 receptors. In fact, osteoblasts have
been reported to release ATP into the extracellular en-
vironment constitutively followed by engagement of P2
receptors [54]. Most importantly, ALP+/CD73+ cells are
also present and even more abundant in freshly isolated
SVFs. The origin of these cells has to be better charac-
terized, but it is reasonable to assume that these cells
could be of pericytic origin. ALP is a known pericytic
marker which was previously described as a marker for
the prospective isolation of pericytes from different tis-
sues [55, 56]. This is in agreement with our observation
that ALP+/CD73+ cells are localized in the capillaries of
fat tissue. In this sense, the difference observed between
“good” and “bad” AD-MSC lines could be explained with
differences in the amount of blood vessels in the isolated
fat tissue. Our data suggest the existence of a balanced
regulation of ALP and CD73 in human AD-MSCs,
which is crucial for the determination of osteogenic
lineage commitment.
In vitro selection after prolonged culture represents a
major concern for the use of MSCs for therapeutic ap-
plications. Expansion on hard tissue culture surfaces
may promote cellular divergence and/or reduction in po-
tency [57, 58]. Additionally, the culture conditions used
are very permissive when compared with the ones
employed by other stem cell types, e.g., embryonic stem
cells or induced pluripotent stem cells, where specific
factors are necessary to maintain the self-renewal cap-
acity of the stem cells [59–61]. Our data indicate that
progressive loss of ALP+/CD73low cells during passa-
ging precludes osteogenic differentiation and constantly
monitoring ALP+/CD73low can be used as a quality
control procedure to monitor AD-MSC expansion for
bone regeneration purposes.
In conclusion, our study highlights that single-cell and
multiparametric analysis identifies gradient expression
and co-localization of markers which have not been pre-
viously observed. The combination of ALP+/CD73low
markers can not only (1) discriminate between “good”
and “bad” differentiating lines but can also be used for
(2) prospective isolation of selected cells from SVF for
bone tissue engineering and (3) to assess the differenti-
ation potential of AD-MSC preparation in culture.
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The use of MSCs in clinical medicine will likely con-
tinue to grow rapidly, yet it still is unclear how clinical
manufacturing affects MSC biology, particularly regard-
ing lineage specification. The development of assays
allowing for the monitoring of the production process
and assessment of cellular function are urgently needed.
The approach chosen in this work might provide a basis
for better understanding how different functional attri-
butes of MSCs are specified at the population level, and
can be used in the development of clinical manufactur-




Adipose-derived stromal cells (AD-MSCs) were obtained
from lipectomies and liposuctions (healthy donors, no dia-
betic donors) upon written informed consent of the do-
nors, following the guidelines approved by the Kantonale
Ethik Kommission (KEK) Zurich Swiss (KEK-ZH: StV 7-
2009) and international ethical guidelines (ClinicalTrials.
gov; Identifier: NCT01218945). The stromal vascular frac-
tion (SVF) isolated from human fat tissue was obtained
with the consent of the patient according to Swiss ethics
(BASEC-Nr.: 2019-01504).
Cells and cell culture
Twenty-two human adipose tissue samples (100–600 g)
were obtained from lipectomies and liposuctions
(healthy donors, no diabetic donors) [62]. AD-MSCs
were isolated from fat tissue, with the consent of the do-
nors according to Swiss (KEK-ZH: StV 7-2009) and
international ethical guidelines (ClinicalTrials.gov; Iden-
tifier: NCT01218945) [62]. The extraction procedure
was performed according to [34]. AD-MSCs were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
(PAN Biotech) supplemented with 10% of fetal bovine
serum (FBS) (Biowest), 1% of antibiotics (100× penicillin,
100× streptomycin) (Biowest), and 1% L-glutamine 200
mM (Sigma) (called AD-MSC medium). Medium was
changed every 3 days, and cells were passaged with 1×
Trypsin-EDTA (Life Technologies) for 5 min at 37 °C
when cells were about 80% confluent. Cells were incu-
bated at 37 °C in an atmosphere with 95% humidity and
5% CO2.
In vitro differentiation of human AD-MSCs
For osteogenic differentiation, AD-MSCs were seeded at
a density of 1.6 × 104 cells/cm2 in Nunc™ 24-well plates
(Thermo Fisher Scientific) or at a density of 1 × 104 in
96-well plates (TPP). For adipogenic differentiation, cells
were cultured at a density of 1.6 × 104 cells/cm2 in
Nunc™ 24-well plates (Thermo Fisher Scientific). Differ-
entiation was started 24 h after seeding with StemPro®
Osteogenesis Kit or StemPro® Adipogenesis Kit (Gibco/
Life Technologies). For chondrogenic differentiation,
cells were cultured at a density of 5 × 103 cells/cm2 in a
Nunc™ 24-well plate (Thermo Fisher Scientific) and dif-
ferentiation was induced at the 4th day of culture using
the StemPro® Chondrogenesis Kit (Gibco/Life Technolo-
gies). All media were changed every 4 days.
Assessment and classification of trilineage differentiation
potential
Differentiation assessment via specific staining was per-
formed for all three differentiation lineages after 14, 17,
and 21 days of differentiation. For Alizarin Red S (Sigma)
staining, cells were washed with PBS and fixed with 4%
(v/v) formaldehyde (Sigma) for 30 min at RT. Upon
washing twice with ddH20, Alizarin Red S solution (0.7 g
Alizarin Red S diluted in 50ml ddH2O at pH = 4.2) was
added for 20 min at RT. Afterwards, cells were washed
four times with ddH2O, dried, and stored in the dark
until image acquisition. For Oil Red O (Sigma) staining,
cells were washed once with PBS and fixed with 10% (v/
v) formaldehyde (Roth) for 1 h at RT. Afterwards, cells
were washed twice with ddH2O, rinsed twice with 60%
(v/v) 2-propanole (Sigma) in ddH20, and dried. Oil Red
O working solution (0.15 g Oil Red O in 50ml 60% (v/v)
2-propanole in ddH2O) was added for 10 min at RT.
After four ddH2O washing steps, cells were dried and
images were directly taken. For Alcian Blue 8GX (Sigma)
staining, cells were washed with PBS and then fixed with
4% (v/v) formaldehyde (Sigma) for 20 min at RT. After-
wards, cells were washed twice with ddH2O and incu-
bated for 3 min with 3% (v/v) acetic acid (Merck
Millipore) in ddH20. Alcian Blue solution (0.1 g Alcian
Blue 8GX in 100 ml of 3% acetic acid in ddH20 at pH =
2.5) was given for 1 h at RT. Cells were washed four
times with ddH2O, dried, and stored in the dark until
image acquisition. Images of the entire wells at days 14,
17, and 21 of differentiation were acquired with Cytation
5 imaging reader (BioTek). Quantification of differenti-
ation was performed according to [35], and subsequent
classification of AD-MSC into “good,” “bad,” and “inter-
mediate” differentiating lines was performed applying
the interquartile range distribution. We defined cell lines
present in the 4th quartile as “good,” lines present in the
2nd and 3rd as “intermediate,” and lines in the 1st quar-
tile as “bad.”
Isolation of the stromal vascular fraction
Stromal vascular fraction (SVF) was isolated from hu-
man fat tissue with the consent of the patient according
to Swiss ethics (BASEC-Nr.: 2019-01504) and according
to [34]. Briefly, lipectomies were cut in small pieces and
extensively washed with PBS. Enzymatic digestion was
performed with 0.075% collagenase I (Gibco) at 37 °C for
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45min in a rotating disk. The reaction was neutralized
with AD-MSC medium and centrifuged at 850g for 10
min. For lysis of the red blood cells, the pellet was incu-
bated for 10 min at RT in 160 mM NH4Cl and then ex-
tensively washed with PBS. The SVF was then filtered
through a 100-μm filter nylon mesh and was either dir-
ectly processed for FACS sorting followed by osteogenic
differentiation, or frozen in AD-MSC medium supple-
mented with 10% DMSO (Sigma).
Fluorescence activating cell sorting (FACS)
AD-MSC lines were washed with PBS and stained with
ALP-APC (R&D) (1/50) and CD73-FITC (Biolegend) (1/
160) for 25 min at 4 °C. Upon washing, the cell fractions
(controls sorted, ALP+/CD73+, ALP−/CD73high, ALP
−/CD73low) were sorted with a FACS BD Aria III 5L
and seeded in Nunc™ 96-well plates (TPP) at a density of
1.2 × 104 cells/cm2 for osteogenic differentiation. Con-
trols sorted were unstained cells processed through the
FACS and collected without sorting specific subpopula-
tions. Differentiation was induced 24 h after seeding.
Freshly isolated SVFs were washed with PBS and stained
with ALP-APC (R&D) (1/50), CD73-FITC (Biolegend)
(1/160), and CD45-PE (Biolegend) (1/160) for 25 min at
4 °C. SVF fractions (controls sorted, CD45−/ALP+/CD73+,
CD45−/ALP−/CD73high, CD45−/ALP−/CD73low) were
sorted with FACS BD Aria III 5L and plated in vitro at a
density of 1 × 104 in 96-well plates (TPP) for osteogenic dif-
ferentiation. All media were changed every 4 days.
Immunohistochemistry and immunofluorescence
Paraffin-embedded samples of human fat tissue were se-
lected for immunohistochemical and immunofluores-
cence analysis. Samples were deparaffinized with xylene
and rehydrated by an increasing ethanol gradient for
hematoxylin and eosin (H&E) staining. Target retrieval
was performed using the PT Link (DAKO) at pH solu-
tion 9.0 (DAKO). Immunohistochemistry staining was
performed using a Dako Autostainer Link 48. Primary
antibodies used were as follows: rabbit monoclonal ALP
(Abcam, 1/200), mouse monoclonal CD73 (Abcam, 1/
200), mouse monoclonal CD31 (DAKO, 1/200), and the
appropriate EnVision HRP secondary antibody (EnVi-
sion HRP rabbit or mouse, DAKO, 1/500) according to
the manufacturer’s instruction. Immunofluorescence was
performed using a Dako Autostainer Link 48 with the
following antibodies: rabbit monoclonal ALP (Abcam, 1/
200), mouse monoclonal CD73 (Abcam, 1/200), Alexa
Fluor 488 goat anti-rabbit IgG (Thermo Fisher, 1/200),
and Alexa Fluor 546 goat anti-mouse IgG (Thermo
Fisher, 1/200) according to the manufacturer’s instruc-
tion. Sections were visualized with LEICA DM6600 with
a × 20 magnifying objective lens.
Mass cytometry antibody panel and staining procedures
The antibody panel consisted of 31 monoclonal anti-
human metal-conjugated antibodies, which included cell
surface, cytoplasmic, and transcription targets (Table S1).
When possible, already metal-conjugated antibodies were
purchased from Fluidigm; otherwise, antibodies were con-
jugated in-house with isotopically pure lanthanide metals
according to the commercially available MaxPar Antibody
Labelling Kit (Fluidigm). Labeled antibodies were stored at
4 °C in antibody stabilizer solution (Candor Bioscience).
Titration of each antibody was performed on a one-to-one
mix of cells consisting of PBMCs (peripheral blood mono-
nuclear cells), HEK (human embryonic kidney cells 293),
Hela (cervical cancer cells), Jurkat (human T lymphocyte
cells), Saos2 (sarcoma cells), Nalm6 (B cell precursor
leukemia cells), SHSY5S (neuroblastoma cells), and hu-
man AD-MSCs. These different cell lines, which we called
MIX, were chosen in order to have for each marker a
positive and a negative control cell type. Sample staining
was performed as described in the MaxPar Cell Surface,
MaxPar Cytoplasmic/Secreted Antigen, and MaxPar Nu-
clear Target protocols (Fluidigm) with minor changes.
Briefly, cells were first subjected to cell surface antibody
staining, followed by cytoplasm staining, and nuclear
staining. For the cytoplasmic and intranuclear staining,
cell fixation steps were shortened to 10min. Cells were
then resuspended in 4% paraformaldehyde (Electron
Microscopy Sciences) and stored at 4 °C until acqui-
sition. In the day of CyTOF acquisition, cells were
washed with MaxPar Fix and Perm Buffer (Flui-
digm) containing Cell-ID Intercalator-IR (Fluidigm)
and incubated at RT for 1 h. Cells were washed
with ddH2O and then diluted in ddH2O with 10%
EQ Calibration Beads (Fluidigm) at 1 million cells/
ml before acquisition with CyTOF 2 mass cyt-
ometer (Fluidigm).
Mass-tag cellular barcoding
For all CyTOF experiments, the Cell-ID 20-Plex Pd Bar-
coding Kit (Fluidigm) was used following the manufac-
tural instructions. In short, 1 million cells per condition
and per line were washed with PBS and then incubated
with Cell-ID Cisplatin (Fluidigm) for 10 min at RT.
Afterwards, cells were fixed with MaxPar Fix Buffer
(Fluidigm) for 10 min at RT, washed with MaxPar
Barcode Perm Buffer (Fluidigm), and incubated with the
appropriate barcode for 30 min at RT. Finally, cells were
washed with Cell Staining Buffer (Fluidigm) and com-
bined depending on the CyTOF experiment in one or
more tubes before antibody staining. Depending on the
planned CyTOF experiment, a specific barcoding strat-
egy was developed in order to minimize technical bias
and highlight biological differences.
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Barcoding strategies for the osteogenic differentiation
experiments
For this differentiation experiment, we had a total of 102
samples. Thus, having only 20 different barcodes avail-
able, we distributed the barcoded samples into 6 tubes
(Tables S2). In each tube when possible, there was one
“good,” one “bad,” and one “intermediate” line for all the
collected time points. The 17 AD-MSC lines cultured
under osteogenic condition were collected during the
first 5 days (day 0, day 1, day 2, day 3, day 4) of differen-
tiation. At each day, the samples were barcoded, pooled
into the appropriate tube, and stored at 4 °C until day 4.
At day 4, a unique antibody master mix was prepared
and distributed into the six tubes. In order to monitor
tube-to-tube variations, we added to each of the six
tubes twice the MIX (PBMCs, HEK, Hela, Jurkat, Saos2,
Nalm6m, SHSY5S, AD-MSCs) for a total of 102 samples
(Tables S2). Stability of the barcoded samples stored at
4 °C during the four collection days was extensively
proved in preliminary tests (data not shown).
Barcoding strategy for prediction of differentiation
potential in five new AD-MSC lines
Five not yet characterized AD-MSC lines (new AD-
MSCs) together with 9 already characterized AD-MSC
lines (reference) were collected in their undifferentiated
state (day 0). Next, together with one MIX, they were all
barcoded according to the barcode plan (Table S3) and
pooled into one single tube for antibody staining and
CyTOF acquisition as described above.
Barcoding strategy for the passage experiment
AD-MSCs F28, F22, F5, and F14 were cultured in AD-
MSC medium in Nunc™ 6-cm plates (Thermo Fisher
Scientific) and passaged when 90% confluence was
reached. This was repeated from passage 3 (p3) to pas-
sage 20 (p20). At each passage, part of the cells was fro-
zen in AD-MSC medium supplemented with 10%
DMSO (Sigma). All AD-MSC lines from p3 to p20 were
thawed the same day and barcoded according to the bar-
code plan (Table S4). All barcoded passages from the
same cell line were pooled into one tube. Each tube con-
tained also twice a MIX as a control. Cells were stained
with the antibody panel following the protocols men-
tioned above and then processed in CyTOF2 (Fluidigm).
Mass cytometry data analysis
Mass cytometry data.fcs files collected from each set of
samples were normalized using the executable MATLAB
version of the Normalizer tool [63] and concatenated
using the .fcs concatenation tool from Cytobank. Indi-
vidual samples were debarcoded using the executable
MATLAB version of the single-cell debarcoder tool [64].
Statistical analyses
Quantification of the staining of the triplicates of undif-
ferentiated cells (control) and cells cultured with differ-
entiation medium (differentiation) is presented as
mean ± s.d. Quantification of the triplicates of the stain-
ing of the FACS sorted subpopulations is presented as
mean ± s.d. For statistical analyses, the one-way ANOVA
Dunnett’s multiple comparisons test was used to com-
pare the ALP+/CD73+ population with the other sorted
fractions within the same day as well as for comparing
the percentage of ALP+, CD73+, and CD271+ cells in
the “good” category for each day with the same day of
the “intermediate” and “bad” ones. *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001, and **** p ≤ 0.0001. Pearson’s correlation
was used to determine the correlation between the ALP
frequency measured by CyTOF at days 0, 1, 2, 3, and 4
with the staining intensity measured at days 14, 17, and
21 for the osteogenic differentiation lineage.
CellCNN analysis
Data pre-processing
Mass cytometry measurements were transformed using
the inverse hyperbolic sine (arcsinh) function with a co-
factor of 5 and subsequently median-centered on a per-
marker basis.
Model training
CellCNN was trained with the objective to classify
“good” versus “bad” AD-MSC lines from their corre-
sponding mass cytometry measurements at day 0 (undif-
ferentiated state). Training examples (multi-cell inputs)
comprised 2000 cells, sampled uniformly at random
from the original mass cytometry samples. In total, we
sampled 1000 training examples per class (“good” or
“bad” cell lines). For the top-k pooling layer, we consid-
ered values of k such that the ratio of k over the multi-
cell input size would be one of [0.5%, 1%, 3%, 5%]. The
remaining CellCNN parameters were set to their default
values.
Defining the selected cell subpopulation
The default CellCNN filter interpretation analysis was
performed to define and characterize the selected cell
subpopulation. Initially, learned filters were clustered
and a single representative filter was retained from each
cluster. As a second step, a score was derived for each
representative filter, measuring how well this filter alone
can classify the validation samples. Only one representa-
tive filter achieved a positive score, and this filter was used
to define the selected cell subpopulation (i.e., cells with
positive score with respect to that filter) in individual mass
cytometry samples at d0, d1, d2, d3, and d4.
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Data availability
Mass cytometry data that support the findings of this
study are available on request from the corresponding
author [P.C.].
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13287-020-02044-4.
Additional file 1: Figure S1. In vitro chondrogenic and adipogenic
categorization of 17 AD-MSCs A) Sum of the pixels acquired at the three
time points (day 14, 17, 21) for chondrogenic (left) and adipogenic (right)
differentiation of all 17 AD-MSC lines and interquartile categorization into
«good», «intermediate», and «bad» AD-MSCs. C) Summary of the
categorization of all 17 AD-MSCs for the three differentiation lineages
(osteogenic, chondrogenic, and adipogenic). interm. = intermediate. Fig-
ure S2. UMAP analyses in the 17 human AD-MSC lines. A) UMAP projec-
tions of all 31 markers in 17 AD-MSC lines. Each dot represents one cell.
Blue denotes minimal, green intermediate, and red high expression. Fig-
ure S3. Analyses of the osteogenic subpopulation. A) Means of the per-
centage of alkaline phosphatase (ALP) positive cells and CD73 positive
cells in the three AD-MSC categories during the five analyzed days of
osteogenic differentiation (d0, d1, d2, d3, d4). Error bars represent the
mean ± s.d. of the percentage of positive cells present in «good» (n = 6),
«intermediate» (n = 4),and «bad» (n = 7) AD-MSCs. B) Pearson correlations
of the ALP frequency measured by CyTOF at day 0, 1, 2, 3, 4 with the
staining intensities measured at day 14, 17, and 21 for osteogenic differ-
entiation. Red dots represent «good», green «intermediate» (interm.), and
black «bad» differentiating lines. Error bars indicate the triplicates of the
staining and are presented as mean ± s.d. For statistical analyses, the
one-way ANOVA Dunnett’s multiple comparisons test was used to com-
pare each day of the “good” AD-MSCs with the same day of “intermedi-
ate” and “bad” categories: * p≤ 0.05, ** p≤ 0.01, *** p ≤ 0.001, and **** p
≤ 0.0001. ns=not significant. Figure S4. ALP+/CD73+ Sorting analysis
and prediction of osteogenic differentiation potential. A) Gating strategy
for FACS sorting for the following subpopulations: ALP+/CD73+, ALP-/
CD73low, and ALP-/CD73high. B) Alizarin Red staining and quantification
of the sorted subpopulations in four AD- MSC lines (F04, F14, F22, F28)
after 14, 17, and 21 days. Control sorted are unstained cells, which were
run through the FACS sorting machine. Depicted are triplicates of undif-
ferentiated cells (control) and cells cultured with the differentiation
medium (differentiation). Error bars indicate the triplicates of the staining
and are presented as mean ± s.d. C) Categorization of the new AD-MSC
lines (depicted in green) together with all the 17 already analyzed lines,
based on Alizarin Red quantification after 14, 17, and 21 days of osteo-
genic differentiation and interquartile distribution of the five new AD-
MSCs (depicted in violet). D) Alizarin Red staining and quantification of
five new AD-MSCs: two «good» (F08, F26), one «intermediate» (F23), and
two «bad» (F20, F24). Depicted are triplicates of undifferentiated cells
(control) and cells cultured under osteogenic differentiation conditions
(differentiation). Error bars indicate triplicates of the staining and are pre-
sented as mean ± s.d. E) Histograms of median intensities of expression
of selected markers (CD73 and ALP) in F05, F14, F22 and F28 AD-MSC
lines from passage 3 (p3) till passage 20 (p20). Black is the lowest inten-
sity and white represents the highest intensity. F) Alizarin Red staining
and quantification of F22 at passage p5, p9, and p20 after 14, 17, and 21
days of osteogenic differentiation. Depicted are triplicates of undifferenti-
ated cells (control) and cells cultured under osteogenic differentiation
medium (differentiation). Error bars indicates the triplicates of the staining
and are presented as mean ± s.d. Figure S5. ALP+/CD73+ cells are
present in the human fat tissue and stromal vascular fraction A)
Hematoxylin/Eosin (H&E) and immunohistochemistry staining of human
fat tissue for ALP, CD73, and CD31. Scale 100 μm. B) Gating strategy for
sorting the selected subpopulations (CD45- /ALP+/CD73+, CD45-/ALP-/
CD73low, CD45-/ALP-/CD73high) in the SVFs. C) Alizarin Red staining and
pixel quantification of sorted SVF fractions (CD45-/ALP+/CD73+, CD45-/
ALP-/CD73low, CD45-/ALP- /CD73high) after 21 days of osteogenic differ-
entiation in vitro. Control sorted are unstained SVFs, which were run
through the FACS sorting machine. Depicted are triplicates of undifferen-
tiated cells (control) and cells cultured with osteogenic differentiation
medium (differentiation). Error bars indicate the triplicates of the staining
and are presented as mean ± s.d. Table S1. Mass cytometry antibody
panel. Table S2. Osteogenic differentiation barcoding schema. Table S3.
Barcoding plan prediction experiment. Table S4: Barcoding plan for the
passage experiment.
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